ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
GlycoMimetics Inc

GlycoMimetics Inc (GLYC)

0.263
-0.0075
(-2.77%)
Closed June 16 4:00PM
0.2626
-0.0004
(-0.15%)
After Hours: 6:10PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.2626
Bid
0.0652
Ask
0.2811
Volume
552,371
0.26 Day's Range 0.2807
0.251 52 Week Range 3.5299
Market Cap
Previous Close
0.2705
Open
0.2719
Last Trade
25
@
0.2629
Last Trade Time
Financial Volume
$ 147,579
VWAP
0.267174
Average Volume (3m)
1,841,078
Shares Outstanding
64,393,294
Dividend Yield
-
PE Ratio
-0.45
Earnings Per Share (EPS)
-0.57
Revenue
10k
Net Profit
-36.9M

About GlycoMimetics Inc

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbo... GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
GlycoMimetics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GLYC. The last closing price for GlycoMimetics was $0.27. Over the last year, GlycoMimetics shares have traded in a share price range of $ 0.251 to $ 3.5299.

GlycoMimetics currently has 64,393,294 shares outstanding. The market capitalization of GlycoMimetics is $16.74 million. GlycoMimetics has a price to earnings ratio (PE ratio) of -0.45.

GLYC Latest News

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant...

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that...

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect...

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To...

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be reported in Q2 2024 New Drug Application (NDA) for uproleselan to be...

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0008-0.3037205770690.26340.290.2515367610.26357103CS
4-0.0204-7.208480565370.2830.310.25110616340.27899994CS
12-2.6374-90.94482758622.93.180.25118410780.69613922CS
26-1.6374-86.17894736841.93.52990.25110455061.09377187CS
52-1.5174-85.24719101121.783.52990.2515850621.1442161CS
156-2.5174-90.55395683452.784.160.2515178101.68478713CS
260-11.0574-97.680212014111.3213.410.2515404752.61390555CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

GLYC Discussion

View Posts
Monksdream Monksdream 1 month ago
GLYC new low
πŸ‘οΈ0
spindog spindog 1 month ago
Well? Good thing i held off on taking a position….
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
Gotta wait it out
πŸ‘οΈ0
spindog spindog 2 months ago
Hopefully the FDA will give GLYC the the green light after reviewing phase 3 data in June
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
GLYC under $2
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
GLYC under $4
πŸ‘οΈ0
willlbone willlbone 1 year ago
Dilution.
πŸ‘οΈ0
INFINITI INFINITI 1 year ago
Reversal
πŸ‘οΈ0
TechandBio TechandBio 1 year ago
Picked up a few heavy racks of shares under 2.95 today.


$GLYC
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 year ago
GLYC: Hey!!!! WHAT???? (HA-HA!!)
πŸ‘οΈ0
makinezmoney makinezmoney 1 year ago
$GLYC: The chart is screaming bullflag breakout on 100day chart

Now at 2.50


Perfect BULL FLAG.


NICE


GO $GLYC
πŸ‘οΈ0
TommyBoyTrader9460 TommyBoyTrader9460 2 years ago
$GLYC Crazy runner here..on watch to see if it continues as insider bought a ton of shares..

https://stocktwits.com/soll/message/497100283

https://stockcharts.com/c-sc/sc?s=GLYC&p=D&b=5&g=0&i=0&r=1668953354914
πŸ‘οΈ0
Invest-in-America Invest-in-America 2 years ago
THANKS!
πŸ‘οΈ0
gail gail 2 years ago
yup and congrats on your other runner.
πŸ‘οΈ0
Invest-in-America Invest-in-America 2 years ago
GO-GO-GO-GLYC!!!

PS: Hey, Girl, tap my latest POSTS behind @GRND --- what a SPECTACLE that one is!!!! (I grabbed their WARRANTS!!)

πŸ‘οΈ0
gail gail 2 years ago
looking good here.
πŸ‘οΈ0
gail gail 2 years ago
wow, new highs hitting right now!
πŸ‘οΈ0
gail gail 2 years ago
and back to 2 bucks. lets see what tomorrow brings.
πŸ‘οΈ0
gail gail 2 years ago
boing, and back up she goes.
πŸ‘οΈ0
gail gail 2 years ago
manipulation bringing it …

..

down but lets see what happens.
πŸ‘οΈ0
gail gail 2 years ago
here we go, breaking 2 bucks big time now.
πŸ‘οΈ0
gail gail 2 years ago
its time to break 2 bucks and really move like it did in the past.
πŸ‘οΈ0
1hot toddy 1hot toddy 2 years ago
WOW WOW WOW CHIEF MEDICAL OFFICIER BOUGHT 200,000 SHARES $$$

he went from 0 shares to 200000 in two days. 2- 100000 shares buys 2 days

now 4 employees have bought shares.
πŸ‘οΈ0
1hot toddy 1hot toddy 2 years ago
WOOOOOOOOOOOOOOOOOW 63000 SHARE BUY $$$$$$$$$$$$$$$$

employees are buying toooooooooo
πŸ‘οΈ0
1hot toddy 1hot toddy 2 years ago
3 HUGE INSIDE BUYS BY 3 PEOPLE. 19K, 20K AND 25K $$$$$$$$$$$$$$$$

1.06/1.29 UP UP AND AWAY
πŸ‘οΈ0
willlbone willlbone 2 years ago
Back to 99 cents.
πŸ‘οΈ0
MfridgeV2 MfridgeV2 3 years ago
Agreed. Things looking up. Load up while no one else wants it. ;)
πŸ‘οΈ0
fishhunter fishhunter 3 years ago
Now is but time. The gap has filled, weak hands are out, corporate path is correct.
πŸ‘οΈ0
mining101 mining101 3 years ago
Depends at what level - if back to 2s first it’s a big loss till then
πŸ‘οΈ0
stockguard stockguard 3 years ago
The Investment Case For GlycoMimetics
https://seekingalpha.com/article/4389595-investment-case-for-glycomimetics
πŸ‘οΈ0
whytestocks whytestocks 4 years ago
News; $GLYC GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition

Data highlight the importance of early intervention with E-selectin inhibitors to disrupt inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) in sickle cell disease (SCD) Additional presentations highlight multiple E-selectin inhibition strategies and their pot...

In case you are interested GLYC - GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition
πŸ‘οΈ0
fishhunter fishhunter 4 years ago
Great buy at this price. I own a ton of it.
πŸ‘οΈ0
whytestocks whytestocks 4 years ago
News; $GLYC New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting

- Data highlight the importance of early intervention with fast-acting E-selectin inhibitors to disrupt the underlying inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) - Abstracts for two of GlycoMimetics’ wholly-owned product candidates, rivipansel and...

In case you are interested GLYC - New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting
πŸ‘οΈ0
420man 420man 4 years ago
No brainer here.. Buy and wait for run to 8's or higher. GL
πŸ‘οΈ0
TheFinalCD TheFinalCD 4 years ago
https://ih.advfn.com/stock-market/NASDAQ/glycomimetics-GLYC/stock-news/82651418/new-efficacy-and-biomarker-data-from-rivipansel-ph
πŸ‘οΈ0
Jwit56 Jwit56 4 years ago
This looks good. Surely this'll bring a lot of growth
πŸ‘οΈ0
whytestocks whytestocks 5 years ago
News: $GLYC GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Piper Jaffrey 31 st Annual Healthcare Conference in New York, New York, which takes place on December 3, 2019. Ms. King’s presentation is scheduled for 1...

In case you are interested GLYC - GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019
πŸ‘οΈ0
The1andonlyt The1andonlyt 5 years ago
New article out on GLYC https://stocksnewswire.com/2019/08/16/glycomimetics-inc-nasdaq-glyc-is-it-ready-to-bounce-after-big-drop-in-price/
πŸ‘οΈ0
@LiftedCapital @LiftedCapital 5 years ago
LONG 2.88 YESTERDAY!!! BOOOOOOOOOOOMAGE
πŸ‘οΈ0
@LiftedCapital @LiftedCapital 5 years ago
GLYC GLAD IM IN.
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $GLYC Video Chart 08-05-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
@LiftedCapital @LiftedCapital 5 years ago
I CAN GIVE A RATS ASS WHY THIS POFS DROPPED. THIS WILL FKN BOUNCE.
πŸ‘οΈ0
Glider549 Glider549 5 years ago
GMI-1070 (rivipansel) Phase 3 data due second half of 2019. Possibly July, or August.
πŸ‘οΈ0
stocktrademan stocktrademan 7 years ago
GLYC buy 11.50









normal chart




log chart



πŸ‘οΈ0
AugustStockInformer AugustStockInformer 7 years ago
Great interview with GLYC CEO: https://www.twst.com/interview/interview-with-the-co-founder-and-ceo-glycomimetics-inc
TWST: When you say rational design, what do you mean by that?

Mrs. King: As contrasted to screening approaches where some people select small molecules by screening millions of compounds against the target, in our case what we are doing instead is understanding the native interaction and how the normal biology works, and then creating a molecule that will interact with that particular target. We are rationally designing it.
πŸ‘οΈ0
stocktrademan stocktrademan 7 years ago
GLYC buy 12.90









normal chart




log chart



πŸ‘οΈ0
biotechnician biotechnician 7 years ago
ASCO first week of June, imo this may see $25+ in June.
πŸ‘οΈ0
UP Trend UP Trend 7 years ago
Monster, and still more news en route.. Perfect squeeze.
πŸ‘οΈ0
G3TCRUNK3R G3TCRUNK3R 7 years ago
Just saw the news! Nicely timed lol.
πŸ‘οΈ0
stockdawg44 stockdawg44 7 years ago
news $16+ , unlucky call there son! GLYC
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock